{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:13:19Z","timestamp":1762546399919,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003810","name":"Hospital de Cl\u00ednicas de Porto Alegre","doi-asserted-by":"publisher","award":["GPPG 2019-0543"],"award-info":[{"award-number":["GPPG 2019-0543"]}],"id":[{"id":"10.13039\/501100003810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001460","name":"Ministry of Home Affairs - Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007380","name":"Funda\u00e7\u00e3o Instituto de Pesquisas Econ\u00f4micas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007380","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jcyt.2024.05.003","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T11:41:43Z","timestamp":1715168503000},"page":"1179-1184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of infused red blood cell volume on major and bidirectional ABO-mismatched bone marrow transplantation"],"prefix":"10.1016","volume":"26","author":[{"given":"Anelise Bergmann","family":"Ara\u00fajo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tissiana","family":"Schmalfuss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Monteiro","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Speransa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa Helena","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Pires Marafon","family":"Franz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.05.003_bib0001","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1097\/TXD.0000000000001179","article-title":"ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes","volume":"7","author":"Valentini","year":"2021","journal-title":"Transplant Direct."},{"key":"10.1016\/j.jcyt.2024.05.003_bib0002","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tracli.2020.06.008","article-title":"Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Ataca Atilla","year":"2020","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0003","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/s41409-019-0496-2","article-title":"ABO blood type incompatibility lost the unfavorable impact on outcome in unrelated bone marrow transplantation","volume":"54","author":"Kimura","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0004","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ajh.24771","article-title":"ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT","volume":"92","author":"Canaani","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.transci.2016.01.008","article-title":"ABO blood group mismatched hematopoietic stem cell transplantation","volume":"54","author":"Tekg\u00fcnd\u00fcz","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0006","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1537-2995.2011.03069.x","article-title":"How do I approach ABO-incompatible hematopoietic progenitor cell transplantation?","volume":"51","author":"Daniel-Johnson","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0007","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/bmt.2014.309","article-title":"Major ABO incompatible BMT in children: Determining what residual volume of donor red cells can safely be infused following red cell depletion","volume":"50","author":"Patrick","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0008","series-title":"The EBMT Handbook","first-page":"163","article-title":"Transfusion Support","author":"Schrezenmeier","year":"2019"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0009","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/bloodadvances.2019000791","article-title":"The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease","volume":"3","author":"Srinagesh","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0010","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/trf.16413","article-title":"Transfusion burden following reduced intensity allogeneic hematopoietic cell transplantation: Impact of donor type","volume":"61","author":"Subramanian","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0011","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/trf.15961","article-title":"Red blood cell and platelet transfusion support in the first 30 and 100 days after allogeneic hematopoietic cell transplant","volume":"60","author":"Yuan","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0012","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/imj.12894","article-title":"Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation","volume":"45","author":"Le Viellez","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0013","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the Intensity of Conditioning Regimens: Working Definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0014","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/trf.13353","article-title":"ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning","volume":"56","author":"Hefazi","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2019.102696","article-title":"Effects of ABO incompatibility on the outcome of allogeneic hematopoietic stem cell transplantation","volume":"59","author":"Parkhideh","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0016","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tmrv.2018.05.005","article-title":"Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study","volume":"32","author":"Ikeda","year":"2018","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0017","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/trf.12572","article-title":"Infusion technique of hematopoietic progenitor cells and related adverse events (CME)","volume":"54","author":"Mulay","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0018","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/trf.15786","article-title":"Hematopoietic cell infusion-related adverse events in pediatric\/small recipients in a prospective\/multicenter study","volume":"60","author":"Ikeda","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0019","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/bjh.18761","article-title":"Donor-type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors","volume":"201","author":"Jarisch","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0020","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00277-021-04571-3","article-title":"Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants","volume":"100","author":"Mehta","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0021","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/trf.15053","article-title":"Donor-type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant","volume":"59","author":"Quek","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0022","first-page":"397","article-title":"Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation","volume":"16","author":"Tomac","year":"2018","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0023","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.13356","article-title":"Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins","volume":"94","author":"Stussi","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2024.05.003_bib0024","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1365-2141.2003.04128.x","article-title":"Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation","volume":"120","author":"Lee","year":"2003","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2024.05.003_bib0025","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1182\/blood-2018-99-115075","article-title":"Donor-Specific Isoagglutinin Clearance in ABO Mismatched Stem Cell Transplant Recipients: How Long Should It Normally Take?","volume":"132","author":"Aneke","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2024.05.003_bib0026","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V96.3.1150","article-title":"Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect","volume":"96","author":"Mielcarek","year":"2000","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924007084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924007084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:09:17Z","timestamp":1762546157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924007084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1465324924007084"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.05.003","relation":{},"ISSN":["1465-3249"],"issn-type":[{"type":"print","value":"1465-3249"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of infused red blood cell volume on major and bidirectional ABO-mismatched bone marrow transplantation","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}